Drug combo shows potential in treating hepatitis C

10/14/2010 | Reuters

The combination of danoprevir and Roche's experimental drug RG7128 appeared safe and well-tolerated in hepatitis C patients compared with placebo during an early-stage study. Those who received the highest doses of both drugs twice a day demonstrated a significant reduction in viral load after 13 days.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Systems Test - V&V Engineer - 14000008LS
Abbott
San Jose, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC